Dyadic International Strikes Major Biotech Deal With Proliant
Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation
Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation
Dyadic Dips on New Partnership With Proliant
Dyadic International, Inc. and Proliant Health and Biologicals Announce Recombinant Albumin Development and Commercialization Partnership
JUPITER, Fla., June 28, 2024 — Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health
Form 144 | Dyadic(DYAI.US) 10% Stockholder Proposes to Sell 657.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 6, $Dyadic(DYAI.US)$ 10% Stockholder Francisco Trust under agreement dated February 28, 1996 intends to sell 292.4K shares of its common stock on Jun 6, with a total market
Dyadic to Attend Industry Events in June
JUPITER, Fla., May 30, 2024 — Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in
Earnings Call Summary | Dyadic(DYAI.US) Q1 2024 Earnings Conference
The following is a summary of the Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript:Financial Performance:Dyadic International closed a $6 million convertible note financing in the fi
Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
Dyadic International Inc (DYAI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review ...
Dyadic | 10-Q: Quarterly report
Dyadic International Q1 EPS $(0.07) Down From $(0.03) YoY, Sales $334.62K Down From $978.05K YoY
Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.07) per share. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year. The company repor
Dyadic Intl Seeing Increased Interest in H5N1 'Bird Flu' Ferritin Nanoparticle Human Vaccine Candidate >DYAI
Dyadic Intl Seeing Increased Interest in H5N1 'Bird Flu' Ferritin Nanoparticle Human Vaccine Candidate >DYAI
Dyadic Intl 1Q R&D Expenses $523,000 >DYAI
Dyadic Intl 1Q R&D Expenses $523,000 >DYAI
Dyadic Intl 1Q Loss/Shr 7c >DYAI
Dyadic Intl 1Q Loss/Shr 7c >DYAI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M
04:01 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $334.6M
Dyadic to Attend Industry and Investor Events in May
JUPITER, Fla., May 08, 2024 — Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address th
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
JUPITER, Fla., April 30, 2024 — Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture o
Dyadic International Files to Sell 3.35M Shares for Holders
Earnings Call Summary | Dyadic(DYAI.US) Q4 2023 Earnings Conference
The following is a summary of the Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript:Financial Performance:Dyadic reported a slight decrease in research and development revenue and lic
Recap: Dyadic International Q4 Earnings
Dyadic International (NASDAQ:DYAI) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:00 PM.Here's what investors need to know about the announcement.EarningsDyadic International misse